OOIR: Observatory of International Research

Papers

(The H4-Index of Pharmacology & Therapeutics is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
WITHDRAWN: 17th International conference on bioactive lipids in cancer, inflammation and related diseases virtual special issue	415
Measuring brain docosahexaenoic acid turnover as a marker of metabolic consumption	302
Editorial Board	296
HIV-associated neurotoxicity and cognitive decline: Therapeutic implications	254
Unlocking the power of affibody conjugated radioactive metallopharmaceuticals for targeted cancer diagnosis and therapy	250
Non-canonical G protein signaling	235
Adenosine receptor signalling as a driver of pulmonary fibrosis	205
Inflammation, lipids, and pain in vulvar disease	204
Collateral lethality: A unique type of synthetic lethality in cancers	199
Endothelial dysfunction as a complication of anti-cancer therapy	173
Potential neonatal toxicity of new psychoactive substances	169
The role of macrophages in asthma-related fibrosis and remodelling	167
Unfolded protein responses: Dynamic machinery in wound healing	162
Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis	161
Exploiting the obesity-associated immune microenvironment for cancer therapeutics	149
New therapeutic horizons for plasma phospholipid transfer protein (PLTP): Targeting endotoxemia, infection and sepsis	141
Matrikines in the skin: Origin, effects, and therapeutic potential	130
In cancer, all roads lead to NADPH	128
Regulatory lipid vicinal diols counteract the biological activity of epoxy fatty acids and can act as biomarkers and mechanisms for disease progression	125
Sulfoconjugation of protein peptides and glycoproteins in physiology and diseases	125
Sleep apnea and pulmonary hypertension: A riddle waiting to be solved	122
Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches	122
Imaging neuroinflammation with TSPO: A new perspective on the cellular sources and subcellular localization	121
Boron in cancer therapeutics: An overview	115
Pharmacological modulation of respiratory control: Ampakines as a therapeutic strategy	113

Contribution of non-selective membrane channels and receptors in epilepsy	103
Management of drug-resistant hypertension as a heterogeneous disorder	101
Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors	100
Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions	97
Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics	95
Novel approaches to target fibroblast mechanotransduction in fibroproliferative diseases	94
Targeting the p38α pathway in chronic inflammatory diseases: Could activation, not inhibition, be the appropriate therapeutic strategy?	92
The phospholipase A2 superfamily as a central hub of bioactive lipids and beyond	92
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets	90
Dysregulation of metabolic pathways in pulmonary fibrosis	90
TLR4 biased small molecule modulators	87
TAAR1 as an emerging target for the treatment of psychiatric disorders	87
Cell-based therapies for vascular regeneration: Past, present and future	87
Novel strategies and promising opportunities for targeted protein degradation: An innovative therapeutic approach to overcome cancer resistance	86
Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives	83
Bispecific antibodies for the treatment of neuroblastoma	82
Natural products that alleviate depression: The putative role of autophagy	81
Corrigendum to “The role of CD71+ erythroid cells in the regulation of the immune response” [Pharmacology & Therapeutics 228 (2021) 107927]	80
Review: Sex-related differences in the treatment of cardiac arrhythmia	80
Editorial Board	80
PGRMC1: An enigmatic heme-binding protein	78
Wnt signaling: A prospective therapeutic target for chronic pain	77
Pharmacological treatment of cardiogenic shock – A state of the art review	73
Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression	73
Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain	70
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents	69
G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)	69
Therapeutic implications of impaired nuclear receptor function and dysregulated metabolism in Wilson's disease	69
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance	68
Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms	68
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors	67
A systematic review on renal effects of SGLT2 inhibitors in rodent models of diabetic nephropathy	67
Targeting Sirtuin1 to treat aging-related tissue fibrosis: From prevention to therapy	67
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases	67
Stabilizing the neural barrier – A novel approach in pain therapy	66
The role of microglia heterogeneity in synaptic plasticity and brain disorders: Will sequencing shed light on the discovery of new therapeutic targets?	66
Signal transduction in primary cilia – analyzing and manipulating GPCR and second messenger signaling	65
DNA methylation in cell plasticity and malignant transformation in liver diseases	65
CircRNAs as upstream regulators of miRNA//HMGA2 axis in human cancer	65
Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines	64
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response	64